MX2016008478A - Nuevo anticuerpo anti adam17 y su uso en el tratamiento del cancer. - Google Patents
Nuevo anticuerpo anti adam17 y su uso en el tratamiento del cancer.Info
- Publication number
- MX2016008478A MX2016008478A MX2016008478A MX2016008478A MX2016008478A MX 2016008478 A MX2016008478 A MX 2016008478A MX 2016008478 A MX2016008478 A MX 2016008478A MX 2016008478 A MX2016008478 A MX 2016008478A MX 2016008478 A MX2016008478 A MX 2016008478A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- antibody
- treatment
- adam17
- novel anti
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un nuevo anticuerpo capaz de unirse al ADAM17 y también las secuencias decodificadoras de aminoácidos y ácidos nucleicos de dicho anticuerpo. En un aspecto, la invención se refiere a un nuevo anticuerpo o fragmentos ligantes de antigenos, capaces de unirse al ADAM17 con actividades antitumorales. La invención también comprende el uso de dicho anticuerpo como un fármaco para el tratamiento del cáncer. Finalmente, la invención comprende composiciones que comprenden dicho anticuerpo, solo o en combinación o conjugado con otros compuestos contra el cáncer, y el uso de los mismos para el tratamiento del cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306860 | 2013-12-24 | ||
| PCT/EP2014/079315 WO2015097287A1 (en) | 2013-12-24 | 2014-12-24 | Novel anti adam17 antibody and its use for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016008478A true MX2016008478A (es) | 2017-01-11 |
Family
ID=49920097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016008478A MX2016008478A (es) | 2013-12-24 | 2014-12-24 | Nuevo anticuerpo anti adam17 y su uso en el tratamiento del cancer. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160326257A1 (es) |
| EP (1) | EP3086808B1 (es) |
| JP (1) | JP2017501723A (es) |
| KR (1) | KR20160093723A (es) |
| CN (1) | CN106029094A (es) |
| AR (1) | AR098953A1 (es) |
| AU (1) | AU2014372539A1 (es) |
| BR (1) | BR112016014882A2 (es) |
| CA (1) | CA2935003A1 (es) |
| MX (1) | MX2016008478A (es) |
| RU (1) | RU2016129198A (es) |
| TW (1) | TW201609814A (es) |
| WO (1) | WO2015097287A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10858441B2 (en) * | 2017-07-12 | 2020-12-08 | University Of Macau | Method of treatment for pancreatic cancer by administering a human-mouse cross-reactive ADAM 17 antibody |
| CN111040032B (zh) * | 2018-10-11 | 2022-11-25 | 中国科学院上海营养与健康研究所 | 双向调节素在制备细胞衰老及肿瘤的诊断或调控制剂中的应用 |
| WO2020185635A1 (en) * | 2019-03-08 | 2020-09-17 | Memorial Sloan Kettering Cancer Center | Adam17 binding molecules and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7960513B2 (en) * | 2004-12-17 | 2011-06-14 | Monash University | Antibody against a human ADAM protease |
| CA2825990A1 (en) * | 2011-02-01 | 2012-08-09 | Cancer Research Technology Limited | Anti-tace antibody molecules and their uses |
-
2014
- 2014-12-23 TW TW103144955A patent/TW201609814A/zh unknown
- 2014-12-23 AR ARP140104902A patent/AR098953A1/es unknown
- 2014-12-24 CN CN201480074117.2A patent/CN106029094A/zh active Pending
- 2014-12-24 CA CA2935003A patent/CA2935003A1/en not_active Abandoned
- 2014-12-24 US US15/107,848 patent/US20160326257A1/en not_active Abandoned
- 2014-12-24 KR KR1020167018548A patent/KR20160093723A/ko not_active Withdrawn
- 2014-12-24 BR BR112016014882A patent/BR112016014882A2/pt not_active Application Discontinuation
- 2014-12-24 AU AU2014372539A patent/AU2014372539A1/en not_active Abandoned
- 2014-12-24 JP JP2016542678A patent/JP2017501723A/ja not_active Withdrawn
- 2014-12-24 EP EP14838861.4A patent/EP3086808B1/en not_active Not-in-force
- 2014-12-24 WO PCT/EP2014/079315 patent/WO2015097287A1/en not_active Ceased
- 2014-12-24 RU RU2016129198A patent/RU2016129198A/ru not_active Application Discontinuation
- 2014-12-24 MX MX2016008478A patent/MX2016008478A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR098953A1 (es) | 2016-06-22 |
| CA2935003A1 (en) | 2015-07-02 |
| EP3086808B1 (en) | 2018-09-19 |
| RU2016129198A (ru) | 2018-01-30 |
| US20160326257A1 (en) | 2016-11-10 |
| WO2015097287A1 (en) | 2015-07-02 |
| JP2017501723A (ja) | 2017-01-19 |
| AU2014372539A1 (en) | 2016-07-21 |
| RU2016129198A3 (es) | 2018-08-21 |
| TW201609814A (zh) | 2016-03-16 |
| KR20160093723A (ko) | 2016-08-08 |
| BR112016014882A2 (pt) | 2017-09-19 |
| CN106029094A (zh) | 2016-10-12 |
| EP3086808A1 (en) | 2016-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121517T1 (el) | Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib | |
| PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| WO2014004549A3 (en) | Anti-mesothelin binding proteins | |
| EP4417263A3 (en) | Cd3 binding antibodies | |
| PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
| MX2018000147A (es) | Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45). | |
| PH12015500390B1 (en) | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis | |
| IN2014KN00848A (es) | ||
| PH12015501284A1 (en) | Bcma antigen binding proteins | |
| MX2022002504A (es) | Anticuerpos para cd40. | |
| TN2015000396A1 (en) | Antibody drug conjugates | |
| IN2014KN00920A (es) | ||
| EA201490644A1 (ru) | Терапевтические пептиды | |
| MX375221B (es) | Composiciones que comprenden anticuerpos anti-molécula de adhesión celular relacionada con antígeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cáncer. | |
| PH12014501410A1 (en) | Compositions and methods for antibodies targeting factor p | |
| MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
| NZ700274A (en) | Anti-pdgf-c antibodies | |
| MX2022000242A (es) | Anticuerpos contra ticagrelor y metodos de uso. | |
| MX2016008478A (es) | Nuevo anticuerpo anti adam17 y su uso en el tratamiento del cancer. | |
| MX2017008475A (es) | Novedoso anticuerpo humanizado adam17. | |
| SA517390221B1 (ar) | Igf-1r الجسم المضاد لـ واستخدامه في تشخيص سرطان | |
| TN2014000207A1 (en) | Anti il-36r antibodies | |
| HK1196856A (en) | C10rf32 antibodies, and uses thereof for treatment of cancer | |
| HK1196831A (en) | Lsr antibodies, and uses thereof for treatment of cancer |